Report of Foreign Issuer (6-k)
February 21 2017 - 7:28AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of February 2017
Commission File Number: 001-36581
Vascular
Biogenics Ltd.
(Translation of registrants name into English)
6 Jonathan Netanyahu St.
Or Yehuda
Israel 6037604
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate by check mark if the
registrant is submitting the
Form 6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the
Form 6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b):
82-
EXPLANATORY NOTE
Attached hereto and incorporated by reference herein is the registrants press release issued on February 21, 2017, entitled VBL Therapeutics
Reports Full Data for
VB-111
Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer. This Report of Foreign Private Issuer on
Form 6-K
shall be
incorporated by reference into the Companys registration statement on
Form F-3
(File No. 333-207250),
filed with the Securities and Exchange
Commission (the SEC) on October 2, 2015, to the extent not superseded by information subsequently filed or furnished (to the extent the Company expressly states that it incorporates such furnished information by reference) by the
Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
VASCULAR BIOGENICS LTD.
|
|
|
|
|
Date: February 21, 2017
|
|
|
|
By:
|
|
/s/ Dror Harats
|
|
|
|
|
|
|
Name:
|
|
Dror Harats
|
|
|
|
|
|
|
Title:
|
|
Chief Executive Officer
|
3
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Sep 2023 to Sep 2024